Based on the results of the DAPA-HF study, Swissmedic has approved dapagliflozin for the treatment of heart failure with reduced ejection fraction (HFrEF), whether or not patients have type 2 diabetes. The SGLT-2 inhibitor significantly reduced the risk of cardiovascular mortality and worsening heart failure in HFrEF patients as an add-on to standard therapy.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Heart failure
Interventional treatment of the tricuspid valve
- Lipoprotein(a)
Current and future treatment options
- Lichen sclerosus
Topical corticosteroids still the first choice
- Breast Cancer
On the trail of triple-negative breast cancer
- Headache treatment
The therapy of migraine
- Sleep disorders in old age
Recognize insomnia, treat it and avoid cognition disorders
- From symptom to diagnosis
Abdominal pain – Pancreatic carcinoma
- Case reports: rare skin tumors